Pulmonary Immune Cell-microbiome Interactions in the Healthy Lung
Recruiting now
Conditions studied: Healthy
In brief
The overall aim is to to provide a normal material for the composition and spatial heterogeneity of the following in the healthy lung: i) immune cell populations and their activation patterns, ii) the surrounding cytokine-chemokine milieu, including trans-compartmental fluxes of these mediators between the lung and bloodstream, and iii) the lung microbiome. Main hypotheses: * Absolute and relative immune cell counts in bronchoalveolar lavage fluid (BALF) are similar to those previously reported by other methods6,7. * No trans-compartmental flux of cytokines between the lungs and bloodstream is present, but cytokine concentrations (notably IL-6 and IL-8) vary with the immune-cell-microbiome composition. * Immune cell (mainly T cell) activation, differentiation, and gene expression patterns are expected to differ between blood and BALF in a manner that depends on the regional diversity of the pulmonary microbiome.
Key facts
- Study ID
- NCT05846620
- Run by
- Hvidovre University Hospital
- People needed
- 50
- Starts
- 2023-04-17
- Expected to finish
- 2028-11-30
- Last updated by the study team
- 2025-03-17
Who can join
Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Men and women
- Age 40 to 75
You may not qualify if…
- Immune deficiency
- Lung disease
- Active cancer or infection
- Absolute contraindications for bronchoscopy
- Untreated malignant arrhythmia
- Documented or suspected intracranial hypertension (intracranial pressure ≥ > 15 mmHg)
- One-lung ventilation
- Severe coagulopathy
Where it is running
- Hvidovre Hospital, University of Copenhagen — Hvidovre, Denmark (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.